D2.219 - Effectiveness of the 300IR house dust mite sublingual tablet in the real-world, non-interventional VORAN study: a responder analysis

The real-world study VORAN confirmed that treatment with the 300IR house dust mite (HDM) sublingual (SLIT) tablet effectively reduced allergic rhinoconjunctivitis (ARC) symptoms and symptomatic medication use, and improved sleep in both adults and adolescents.¹ Here we explored the patient profile, effectiveness and safety of the 300IR HDM SLIT-tablet in treatment responders.

¹Pfaar et al. Allergy 2025;80(S114):S233

In this large prospective, multicentre, observational, non-interventional study, patients with moderate to severe HDM ARC with or without concomitant asthma receiving the 300IR HDM SLIT-tablet were classified as higher responders (HR) and lower responders (LR) at the end of the first treatment year (Visit 5). HR were defined as patients with an at least 2-point difference from baseline in ARC score (range 0–6) based on the severity of nasal and eye symptoms, each group assessed on a 0–3 scale (0=none, 1=mild, 2=moderate, 3=severe). Baseline data, severity of symptoms, use of symptomatic medication, impact of HDM allergy on sleep, patient well-being, safety and tolerability were described in both subgroups.

Of 495 patients with Visit 5 data, 367 (74.1%) and 128 (25.9%) were classified as HR and LR, respectively.

At baseline (Visit 1), patient characteristics were largely comparable between both subgroups (Table). Besides, HR reported more moderate to severe nasal and eye symptoms (93.2% and 46.9%) than LR (73.4% and 12.5%). Moderate to severe lung symptoms were present in equal proportions in both subgroups (20.7% and 20.3%). HR took slightly more symptomatic ARC medication (mainly nasal corticosteroids) than LR. 94.8% of HR reported impaired sleep vs 89.1% of LR.

At Visit 5, larger proportions of patients being either symptom-free or showing an improvement in symptom severity vs. baseline were observed in HR for nasal (97.8% vs 59.2% in LR), eye (95.9% vs 27.0%) and lung (86.5% vs 67.2%) symptoms. Symptomatic medication use decreased in both subgroups with 59.8% HR vs 35.6% LR able to discontinue any ARC medication. Treatment led to improved sleep (85% HR vs 60.2% LR). A great majority of HR (96.7%) assessed their well-being as much better or somewhat better (vs 85.9% LR). The safety and tolerability were good in both subgroups.

This study confirmed the effectiveness of 300IR HDM SLIT-tablet in HDM ARC patients, especially in those with more frequent and severe symptoms, and more pronounced impact of HDM on sleep at baseline.